Safety issues related to emerging therapies for rheumatoid arthritis

E.C. Keystone

ABSTRACT
Several novel biologic therapies for rheumatoid arthritis (RA) are emerging that target aspects of the immune system other than tumor necrosis factor (TNF). Two such therapies currently in development include CTLA4Ig (Abatacept) and anti-CD20 monoclonal antibody (Rituximab). CTLA4Ig has been demonstrated to be well tolerated with a good short-term safety profile. Rituximab has also been shown to have a good safety profile in a limited number of RA patients. Further safety data with larger numbers of RA patients treated with Rituximab is required.

Key words
Rheumatoid arthritis, Rituximab (anti-CD20), biologics therapy, Abatacept (CTLA4Ig).

Edward C. Keystone, MD, FRCP(C), Professor of Medicine, University of Toronto, Director, The Division of Advanced Therapeutics.
Please address correspondence to: Prof. Edward C. Keystone, MD, FRCP(C), The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, Ontario M5G 1X5, Canada.

Clin Exp Rheumatol 2004; 22 (Suppl. 35): S148-S150.
© Copyright Clinical and Experimental Rheumatology 2004.